內(nèi)科學(xué)淋巴瘤鄒善華_第1頁(yè)
內(nèi)科學(xué)淋巴瘤鄒善華_第2頁(yè)
內(nèi)科學(xué)淋巴瘤鄒善華_第3頁(yè)
內(nèi)科學(xué)淋巴瘤鄒善華_第4頁(yè)
內(nèi)科學(xué)淋巴瘤鄒善華_第5頁(yè)
已閱讀5頁(yè),還剩33頁(yè)未讀 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

內(nèi)科學(xué)淋巴瘤鄒善華Definition:AgroupofneoplasticdiseasesoflymphoidtissuesClassification:

Hodgkin′sDisease,HD(Hodgkin′sLymphoma)NonHodgkin′sLymphoma,NHL)GeneralConsiderations2021/4/272ClinicalFeatures:

Painless,progressivelymphadenectasisFever,weightloss,nightsweat;cachexiaHepatosplenomegalyEpidemiology:

Incidence:incities/inthecountry;male/female;ageHD8~11%;NHL90%GeneralConsiderations2021/4/273Virulogy:

EBvirus→Burkittlymphoma,HD

HumanT-cellLymphotropicVirustype1,HTLV-1→AdultT-celllymphoma/leukemia,ATL

HTLV-2→MycosisFungoidesHelicobacterPylori→MALTlymphomaKaposisarcoma-associatedherpesvirus→primarybodycavitylymphoma

EtiologyandPathogenesis

2021/4/274ImmuneStatesofHost:

Immunodeficiency/immunosuppressionMechanism:Antigenicstimulation→

lymphadenosis(modulation↓)→infiniteproliferation→lymphomaEtiologyandPathogenesis2021/4/275ClassificationofLymphomaHD:Reed-Sternberg(R-S)Cell

2021/4/276ClassificationofLymphoma

RyeClassification,1966LymphocytepredominanceNodularsclerosisMixedcellularityLymphocytedepletion2021/4/277ClassificationofLymphoma

WHOClassification,2001NodularlymphocytepredominanceHodgkin'slymphomaClassicalHodgkin'slymphomaLymphocyte-richclassicalHodgkin'slymphomaNodularsclerosisHodgkin'slymphomaMixedcellularityHodgkin'slymphomaLymphocytedepletionHodgkin'slymphoma2021/4/278ClassificationofLymphomaNHL:2021/4/279ClassificationofLymphomaNHL:

IWF,1982REAL,1994WHO,20012021/4/2710WorkingFormulation

Low-gradelymphomaA.smalllymphocytic,consistentwithchroniclymphocyticleukemiaplasmacytoidB.follicular,predominantlysmallcleavedcelldiffuseareassclerosisC.

follicular,mixedsmallcleavedandlargecelldiffuseareas

sclerosis2021/4/2711WorkingFormulationIntermediate-gradlymphomaD.

follicular,predominantlylargecelldiffuseareassclerosisE.diffuse,smallcleavedcellsclerosisF.

diffuse,mixedsmallandlargecellsclerosisepithelioidcellcomponentG.

diffuse,largecellcleavedcellnoncleavedcellsclerosis

2021/4/2712WorkingFormulationHigh-gradelymphomaH.mmunoblastic,largecellplasmacytoidclearcellpolymorphousepithelioidcellcomponentI.lymphoblastic,convolutedornonconvolutedcellJ.smallnoncleavedcell,Burkitt'sornon-Burkitt's2021/4/2713WorkingFormulationMiscellaneouscompositemycosisfungoideshistiocyticextramedullaryplasmacytomaunclassifiableother2021/4/2714REALClassification

B-cellneoplasmsI.PrecursorB-cellneoplasm:precursorB-lymphoblasticleukemia/lymphomaII.PeripheralB-cellneoplasms

A.B-cellchroniclymphocyticleukemia/prolymphocyticleukemia/smalllymphocyticlymphomaB.Lymphoplasmacytoidlymphoma/immunocytomaC.MantlecelllymphomaD.Folliclecentercelllymphoma,follicular1.Provisionalcytologicgrades:Ismallcell,IImixedsmallandlargecell,IIIlargecell2.Provisionalsubtype:diffuse,predominantlysmallcelltype

2021/4/2715REALClassificationE.MarginalzoneB-celllymphoma1.Extranodal(MALT-type+/-monocytoidBcells)2.Provisionalsubtype:nodal(+/-monocytoidBcells)F.Provisionalentity:splenicmarginalzonelymphoma(+/-villouslymphocytes)G.HairycellleukemiaH.Plasmacytoma/plasmacellmyelomaI.DiffuselargeB-celllymphoma1.Subtype:primarymediastinal(thymic)B-celllymphomaJ.Burkitt’slymphomaK.Provisionalentity:high-gradeB-celllymphoma,Burkitt-like

2021/4/2716REALClassificationT-cellandputativeNK-cellneoplasmsI.PrecursorT-cellneoplasm:precursorT-lymphoblasticlymphoma/leukemiaII.PeripheralT-cellandNK-cellneoplasmsA.T-cellchroniclymphocyticleukemia/prolymphocyticleukemiaB.Largegranularlymphocyteleukemia1.T-celltype2.NK-celltypeC.Mycosisfungoides/Sezary’syndrome2021/4/2717REALClassification

D.PeripheralT-celllymphomas,unspecified1.Provisionalcytologiccategories:medium-sizedcell,mixedmediumandlargecell,largecell,lymphoepithelioidcell2.Provisionalsubtype:hepatosplenicgamma/deltaT-celllymphoma3.Provisionalsubtype:subcutaneouspanniculiticT-celllymphomaE.AngioimmunoblasticTcelllymphomaF.Angiocentriclymphoma2021/4/2718REALClassification

G.IntestinalT-celllymphoma(+/-enteropathyassociated)H.AdultT-celllymphoma/leukemiaI.Anaplasticlargecelllymphoma1.CD30+-celltype2.T-celltype3.Null-celltypesJ.Provisionalentity:anaplasticlargecelllymphoma,Hodgkin's-like

2021/4/2719WHOClassification,2001B-cellneoplasmsI.PrecursorB-cellneoplasm:

a.PrecursorB-lymphoblasticleukemia/lymphomaII.Mature(peripheral)B-cellneoplasmsaB-cellchroniclymphocyticleukemia/smalllymphocyticlymphoma

bB-cellprolymphocyticleukemiacLymphoplasmacyticlymphoma

dSpenicmarginalzoneB-celllymphoma(+/-villouslymphocytes)eNodalmarginalzonelymphoma(+/-monocytoidB-cells)fExtranodalmarginalzoneB-celllymphomaof

mucosa-associatedlymphoidtissue(MALT)type

2021/4/2720WHOClassification,2001

gHairycellleuekmiahPlasmacellmyeloma/plasmacytomaiFollicularlymphoma,folliclecenterjMantlecelllymphomakDiffuselargecellB-celllymphomaMediastinallargeB-celllymphomaIntravascularlargeB-celllymphomaPrimaryeffusionlymphomalBurkitt'slymphoma/Burkitt'scellleukemiaB-cellproliferationsofuncertainmalignantpotential

Lymphomatoidgranulomatosis

Post-transplantlymphoproliferativedisorder

2021/4/2721WHOClassification,2001T-CellandNaturalKillerCellNeoplasmsI.PrecursorTcellneoplasm:

a.PrecursorT-lymphoblasticlymphoma/leukemia

b.BlasticNKlymphoma2021/4/2722WHOClassification,2001II.Mature(peripheral)TcellandNK-cellneoplasmsaTcellprolymphocyticleukemiabT-cellgranularlymphocyticleukemiacAggressiveNKCellleukemiadAdultTcelllymphoma/leukemia(HTLV1+)eExtranodalNK/T-celllymphoma,nasaltypefEnteropathy-typeT-celllymphomagHepatosplenicgamma-deltaT-celllymphomahSubcutaneouspanniculitis-likeT-celllymphomaiMycosisfungoides/Sezary'ssyndrome2021/4/2723WHOClassification,2001

jPrimaryCutaneousAnaplasticlargecelllymphomaT/nullcellkPeripheralTcelllymphoma,unspecifiedlAngioimmunoblasticTcelllymphomamPrimarySystemicAnaplasticlargecelllymphoma,T/nullcellT-cellproliferationofuncertainmalignantpotential

Lymphomatoidpapulosis2021/4/2724ClinicalFeatures2021/4/2725

HDNHL

Age

Youngpeople

Moreofteninmiddle-agedpeople

Superficiallymphnodes

60~80%

50%

(firstobservedastumefactionofcervicalorsupraclavicularlymphnodes)

Mediastinallymphnodes

50%

20%

Retroperitoneallymphnodes

Seldominvaded

Ofteninvaded

Fever

Oftenoccurred

Seldominearlyperiod

Itchofskin

Oftenoccurredinsomeyoungfemalepatients

Seldomoccurred

Specificskinlesion

Seldomoccurred

OftenoccurredExtranodalsites

Seldomoccurred

Oftenoccurred

(Waldeyer’sring,gastrointestinaltract,bonemarrow,CNS,liver,lung,pleura,bone,skin,kidney)

Wayofdissemination

Metastasistonearbylymphnodes

Inajumpingway

Bonemarrowinvolvement

SeldomoccurredOftenoccurred

Progress

Slower

Faster

Prognosis

Better

Worse

2021/4/2726LabandOtherFindingsPeripheralBloodandBoneMarrowHD:Eosinophilia;R-Scell NHL:Lymphocytosis;ComplicatedleukemiaLDH,β2-MG,Coombstest,globulinRadiologicstudiesChestX-rayCT,MRIRadioactivenuclidePET-CTB-ultrasoundBiopsyImmunophenotypeCytogeneticandMolecularStudies2021/4/2727Diagnosis

Painless,progressivelymphadenectasis→Biopsy

SkinLesion→BiopsyBoneMarrowAspirationandBiopsyBiopsyofOtherSites

DiagnosisandDifferentialDiagnosis2021/4/2728StagingoflymphomaStageDefinitionⅠInvolvementofasinglelymphnoderegionorofasingleextranodalorganorsite(ⅠE)ⅡInvolvementoftwoormorenoderegionsonthesamesideofthediaphragm,orlocalizedinvolvementofanextranodalsiteororgan(ⅡE)andoneormorelymphnoderegionsonthesamesideofthediaphragmⅢInvolvementoflymphnoderegionsonbothsidesofthediaphragmwhichmayalsobeaccompaniedbylocalizedinvolvementofanextranodalorgansorsite(ⅢE)orspleen(Ⅲs)orboth(ⅢsE)ⅣDiffuseordisseminatedinvolvementofoneormoredistantextranodalorganswithorwithoutassociatedlymphnodeinvolvementBsymptomsFever>38℃,nightsweats,and/orweightloss>10%ofbodyinthe6months2021/4/2729Stagingoflymphoma2021/4/2730DifferentialDiagnosisLymphadenectasis:

ChroniclymphadenitisTuberculouslymphadenitisTumournodemetastasesFever:Septicaemia,Tuberculosis,RheumaticdiseaseExtranodalLymphoma:OthermalignanttumerDiagnosisandDifferentialDiagnosis2021/4/2731RadiationTherapy

60Co,acceleratorlinearDosage:30~40GY,3~4WMethods:

Localfieldirradiation(LFI)

MantleorinvertedYirradiationTotalnodalirradiation(TNI)Treatment2021/4/2732TreatmentFields2021/4/2733Indication:HDⅠA,ⅡA:Extendedfieldirradiation(EFI)ⅠB,ⅡB,ⅢA:TNIand/orcombination

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論